758 related articles for article (PubMed ID: 33162029)
21. Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism.
Chiou JF; Tai CJ; Wang YH; Liu TZ; Jen YM; Shiau CY
Cancer Biol Ther; 2009 Oct; 8(20):1904-13. PubMed ID: 19770576
[TBL] [Abstract][Full Text] [Related]
22. Co-Delivery of siNRF2 and Sorafenib by a "Click" Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma.
Tong R; Feng X; Sun J; Ling Z; Wang J; Li S; Yang B; Deng J; He G; Wu J
Small; 2024 May; 20(21):e2307273. PubMed ID: 38102096
[TBL] [Abstract][Full Text] [Related]
23. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
[TBL] [Abstract][Full Text] [Related]
24. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
[TBL] [Abstract][Full Text] [Related]
25. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
Huang W; Chen K; Lu Y; Zhang D; Cheng Y; Li L; Huang W; He G; Liao H; Cai L; Tang Y; Zhao L; Pan M
Neoplasia; 2021 Dec; 23(12):1227-1239. PubMed ID: 34768109
[TBL] [Abstract][Full Text] [Related]
26. Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.
Jian C; Fu J; Cheng X; Shen LJ; Ji YX; Wang X; Pan S; Tian H; Tian S; Liao R; Song K; Wang HP; Zhang X; Wang Y; Huang Z; She ZG; Zhang XJ; Zhu L; Li H
Cell Metab; 2020 May; 31(5):892-908.e11. PubMed ID: 32375062
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma.
Zhang L; Li XM; Shi XH; Ye K; Fu XL; Wang X; Guo SM; Ma JQ; Xu FF; Sun HM; Li QQ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2023 Mar; 44(3):622-634. PubMed ID: 36109580
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
Liu G; Kuang S; Cao R; Wang J; Peng Q; Sun C
FASEB J; 2019 Sep; 33(9):10089-10103. PubMed ID: 31199678
[TBL] [Abstract][Full Text] [Related]
30. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma.
Ou W; Mulik RS; Anwar A; McDonald JG; He X; Corbin IR
Free Radic Biol Med; 2017 Nov; 112():597-607. PubMed ID: 28893626
[TBL] [Abstract][Full Text] [Related]
31. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
Feng J; Lu PZ; Zhu GZ; Hooi SC; Wu Y; Huang XW; Dai HQ; Chen PH; Li ZJ; Su WJ; Han CY; Ye XP; Peng T; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Jan; 42(1):160-170. PubMed ID: 32541921
[TBL] [Abstract][Full Text] [Related]
32. DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma.
Kim DH; Kim MJ; Kim NY; Lee S; Byun JK; Yun JW; Lee J; Jin J; Kim J; Chin J; Cho SJ; Lee IK; Choi YK; Park KG
BMB Rep; 2022 Nov; 55(11):547-552. PubMed ID: 36016501
[TBL] [Abstract][Full Text] [Related]
33. Polyphyllin I induced ferroptosis to suppress the progression of hepatocellular carcinoma through activation of the mitochondrial dysfunction via Nrf2/HO-1/GPX4 axis.
Yang R; Gao W; Wang Z; Jian H; Peng L; Yu X; Xue P; Peng W; Li K; Zeng P
Phytomedicine; 2024 Jan; 122():155135. PubMed ID: 37856990
[TBL] [Abstract][Full Text] [Related]
34. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis.
Ren X; Li Y; Zhou Y; Hu W; Yang C; Jing Q; Zhou C; Wang X; Hu J; Wang L; Yang J; Wang H; Xu H; Li H; Tong X; Wang Y; Du J
Redox Biol; 2021 Oct; 46():102122. PubMed ID: 34482117
[TBL] [Abstract][Full Text] [Related]
35. Solasonine promotes ferroptosis of hepatoma carcinoma cells via glutathione peroxidase 4-induced destruction of the glutathione redox system.
Jin M; Shi C; Li T; Wu Y; Hu C; Huang G
Biomed Pharmacother; 2020 Sep; 129():110282. PubMed ID: 32531676
[TBL] [Abstract][Full Text] [Related]
36. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
Coriat R; Nicco C; Chéreau C; Mir O; Alexandre J; Ropert S; Weill B; Chaussade S; Goldwasser F; Batteux F
Mol Cancer Ther; 2012 Oct; 11(10):2284-93. PubMed ID: 22902857
[TBL] [Abstract][Full Text] [Related]
38. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
39. Targeted degradation of NDUFS1 by agrimol B promotes mitochondrial ROS accumulation and cytotoxic autophagy arrest in hepatocellular carcinoma.
Dong L; Luo L; Wang Z; Lian S; Wang M; Wu X; Fan J; Zeng Y; Li S; Lv S; Yang Y; Chen R; Shen E; Yang W; Li C; Wang K
Free Radic Biol Med; 2024 Aug; 220():111-124. PubMed ID: 38697493
[TBL] [Abstract][Full Text] [Related]
40. Brusatol induces ferroptosis to inhibit hepatocellular carcinoma progression by targeting ATF3.
Wan Y; Cheng J; Gan D; He J; Chen A; Ma J; Li Y; Wang X; Ran J; Chen D; Li J
Chem Biol Drug Des; 2024 Jun; 103(6):e14565. PubMed ID: 38862254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]